Published in Semin Dial on June 11, 2012
Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis. Expert Opin Ther Targets (2015) 0.81
Trends in Anemia Management in Hemodialysis Patients with Cancer. Am J Nephrol (2015) 0.75
Blood transfusion, serum ferritin, and iron in hemodialysis patients in Africa. J Blood Transfus (2015) 0.75
Evaluation of the humoral immune response to human leukocyte antigens in Brazilian renal transplant candidates. PLoS One (2014) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Transfusion-related acute lung injury: definition and review. Crit Care Med (2005) 3.98
The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol (2007) 2.45
A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant (2006) 2.37
Noninfectious serious hazards of transfusion. Anesth Analg (2009) 2.21
RENAL HOMOGRAFTS IN PATIENTS WITH MAJOR DONOR-RECIPIENT BLOOD GROUP INCOMPATIBILITIES. Surgery (1964) 2.16
Sepsis associated with transfusion of red cells contaminated with Yersinia enterocolitica. Transfusion (1990) 2.13
Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant (2002) 2.01
A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol (1995) 2.01
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 1.92
Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis (2001) 1.89
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation (2000) 1.85
Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med (1995) 1.65
All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation (2002) 1.58
Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease. Transfus Med (1998) 1.42
Bacteria in blood for transfusion. A review. Arch Pathol Lab Med (1994) 1.34
Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion (2009) 1.30
Reducing noninfectious risks of blood transfusion. Anesthesiology (2011) 1.30
Probability of anti-D development in D- patients receiving D+ RBCs. Transfusion (2003) 1.21
Red cell alloimmunization in multi-transfused chronic renal failure patients undergoing hemodialysis. Indian J Pathol Microbiol (1999) 1.17
Current risk for transfusion transmitted infections. Curr Opin Hematol (2007) 1.17
Transfusion haemosiderosis and chelation therapy. Clin Haematol (1982) 1.15
Transfusion-related sepsis due to Serratia liquefaciens in the United States. Transfusion (2000) 1.11
Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation (1994) 1.09
Transfusion-associated hyperkalemia. Transfus Med Rev (2011) 1.07
Analysis of immune response to red blood cell antigens in multitransfused patients with different diseases. Mater Med Pol (1991) 1.05
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol (2012) 1.03
Risks of transfusion. South Med J (2011) 1.02
Primary immunization of Rh-negative volunteers. Br Med J (1970) 1.00
Blood product-associated bacterial sepsis. Transfus Med Rev (1991) 0.97
Antibodies and human transplant rejection. Ann Surg (1969) 0.92
Red cell alloimmunization in chronic renal failure patients undergoing hemodialysis. Nephron (1988) 0.91
Transfusion-related bacterial sepsis. Curr Opin Hematol (2001) 0.89
Primary rhesus immunization of male volunteers. Br J Haematol (1971) 0.84
Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol (1994) 0.84
Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion (2002) 0.82
High-dose intravenous immunoglobulin for post-transfusion purpura. Scand J Haematol (1983) 0.82
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis (2008) 0.80
Successful treatment of transfusion-associated graft-versus-host disease. Br J Haematol (1994) 0.79
Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int (1989) 0.78
Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Vox Sang (1999) 0.77
High-dose intravenous immunoglobulin for post-transfusion purpura. N Engl J Med (1983) 0.77
Failure of deferoxamine to improve iron overload in chronic hemodialysis patients. Int J Artif Organs (1990) 0.76
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. Am J Kidney Dis (2009) 2.61
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis (2010) 1.93
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int (2005) 1.91
Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int (2005) 1.89
Creatinine generation is reduced in patients requiring continuous venovenous hemodialysis and independently predicts mortality. Nephrol Dial Transplant (2012) 1.71
Single-center experience with the Arrow-Trerotola Percutaneous Thrombectomy Device in the management of thrombosed native dialysis fistulas. J Vasc Interv Radiol (2005) 1.59
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.49
The renal manifestations of thyroid disease. J Am Soc Nephrol (2011) 1.46
Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial (2010) 1.44
Are we paying our housestaff fairly? Ann Surg (2014) 1.40
NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol (2007) 1.36
Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial (2004) 1.29
Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther (2006) 1.29
Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol (2012) 1.24
Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics (2005) 1.22
Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant (2007) 1.20
Recruitment of live donors by candidates for kidney transplantation. Clin J Am Soc Nephrol (2008) 1.01
Complications of percutaneous treatment of thrombosed hemodialysis access grafts. Semin Dial (2003) 1.00
The impact of documentation of severe acute kidney injury on mortality. Clin Nephrol (2013) 0.99
Dialysis versus nondialysis in patients with AKI: a propensity-matched cohort study. Clin J Am Soc Nephrol (2014) 0.99
Handoff communication between hospital and outpatient dialysis units at patient discharge: a qualitative study. Jt Comm J Qual Patient Saf (2013) 0.95
Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95
Willingness of patients to switch from conventional to daily hemodialysis: looking before we leap. Am J Med (2004) 0.91
Development, implementation, and results of the ASN in-training examination for fellows. Clin J Am Soc Nephrol (2009) 0.90
Should nephrology training programs continue to train fellows in the placement of temporary hemodialysis catheters? Semin Dial (2014) 0.90
Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int (2004) 0.89
The safety of heparins in end-stage renal disease. Semin Dial (2006) 0.88
Use of antiepileptic drugs in patients with kidney disease. Semin Dial (2006) 0.87
Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol (2012) 0.86
How can erythropoietin requirements be reduced in dialysis patients? Semin Dial (2006) 0.82
Quinine--a tonic too bitter for hemodialysis-associated muscle cramps? Semin Dial (2007) 0.82
Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis (2003) 0.81
Extracorporeal treatment of cast nephropathy. Semin Dial (2011) 0.80
Niacin and related compounds for treating hyperphosphatemia in dialysis patients. Semin Dial (2008) 0.80
Impact of tip culture on the management of infected tunneled hemodialysis catheters. J Vasc Interv Radiol (2007) 0.79
Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysis. Kidney Int (2004) 0.79
Initiating dialysis at the right time: is the evidence IDEAL? Semin Dial (2010) 0.79
KDOQI in the era of global guidelines. Am J Kidney Dis (2009) 0.79
Arterial stiffness and vascular calcification in dialysis patients: new measures of cardiovascular risk. Semin Dial (2007) 0.78
Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc Med (2011) 0.77
Staphylococcus-infected tunneled dialysis catheters: is over-the-wire exchange an appropriate management option? Cardiovasc Intervent Radiol (2011) 0.76
A decade after the KDOQI CKD guidelines: impact on NKF-KDOQI. Am J Kidney Dis (2012) 0.76
Should all patients with chronic kidney disease receive an EPO-type drug? Cleve Clin J Med (2006) 0.76
The ASN in-training examination needs more time, not a new paradigm. Clin J Am Soc Nephrol (2010) 0.75
Can continuous venovenous hemofiltration prevent contrast-induced nephropathy: is the dye already cast? Semin Dial (2007) 0.75
Activated vitamin D: does it explain an apparent survival advantage among black and hispanic hemodialysis patients? Semin Dial (2008) 0.75
How much is enough? The impact of frequent hemodialysis. Semin Dial (2008) 0.75
Erythropoietin bundling: innovative remuneration or the dawn of EPO-profiling? Semin Dial (2010) 0.75
Can frequent hemodialysis be too frequent? J Am Soc Nephrol (2013) 0.75
Impact of obstructive sleep apnea in hemodialysis patients. Semin Dial (2009) 0.75
Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis (2013) 0.75
Is hemodialysis bad for the heart? Semin Dial (2012) 0.75
When chronic kidney disease becomes advanced. Guidelines for care in the emergency department and hospital. Postgrad Med (2006) 0.75
Boning up on lanthanum. Semin Dial (2006) 0.75
Is intravenous iron safe in patients with liver disease? Semin Dial (2002) 0.75
Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Semin Dial (2004) 0.75
Do oral iron supplements have any role in dialysis patients? Semin Dial (2011) 0.75
Are inflammatory cytokines the "evil humors" that increase morbidity and cardiovascular mortality in chronic kidney disease? Semin Dial (2005) 0.75
How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis? Semin Dial (2006) 0.75
Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients. Semin Dial (2005) 0.75
Measuring vitamin, mineral, and trace element levels in dialysis patients. Semin Dial (2014) 0.75